A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-07
DOI
10.1186/s12967-020-02680-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
- (2020) Patrick Schummer et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma
- (2019) Margaret Ottaviano et al. VIRCHOWS ARCHIV
- Genomic features of exceptional response in vemurafenib ± cobimetinib-treated patients with BRAFV600-mutated metastatic melanoma
- (2019) Yibing Yan et al. CLINICAL CANCER RESEARCH
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Immunological effects of BRAF+MEK inhibition
- (2018) Paolo A. Ascierto et al. OncoImmunology
- 1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
- (2018) P A Ascierto et al. ANNALS OF ONCOLOGY
- Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
- (2018) Maria Elena Pisanu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
- (2017) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
- (2016) Francesco Sabbatino et al. JNCI-Journal of the National Cancer Institute
- Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
- (2016) Francesco Sabbatino et al. JNCI-Journal of the National Cancer Institute
- 25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study
- (2015) G. McArthur et al. EUROPEAN JOURNAL OF CANCER
- Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
- (2015) David R. Minor et al. Pigment Cell & Melanoma Research
- Melanoma
- (2015) Dirk Schadendorf et al. Nature Reviews Disease Primers
- Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment
- (2014) Kousaku Mimura et al. CANCER SCIENCE
- Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases
- (2014) Anna Sophie Berghoff et al. HISTOPATHOLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”
- (2013) Paolo A Ascierto et al. Journal of Translational Medicine
- Influence of tumour micro-environment heterogeneity on therapeutic response
- (2013) Melissa R. Junttila et al. NATURE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
- (2013) Bishu Sapkota et al. OncoImmunology
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
- (2010) S. Mocellin et al. JNCI-Journal of the National Cancer Institute
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started